Hydrochlorothiazide
- Generic Name
- Hydrochlorothiazide
- Brand Names
- Accuretic, Actelsar Hct, Aldactazide, Altace HCT, Atacand, Atacand Hct, Avalide, Benicar Hct, Diovan Hct, Exforge Hct, Hyzaar, Ifirmacombi, Karvezide, Lopressor Hct, Lotensin Hct, Maxzide, Micardis-hct, Olmetec Plus, Tekturna Hct, Teveten HCT, Tribenzor, Urozide, Vaseretic, Viskazide, Zestoretic, Ziac
- Drug Type
- Small Molecule
- Chemical Formula
- C7H8ClN3O4S2
- CAS Number
- 58-93-5
- Unique Ingredient Identifier
- 0J48LPH2TH
- Background
Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension. Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and angiotensin converting enzyme inhibitors or angiotensin II receptor blockers.
Hydrochlorothiazide was granted FDA approval on 12 February 1959.
- Indication
Hydrochlorothiazide is indicated alone or in combination for the management of edema associated with congestive heart failure, hepatic cirrhosis, nephrotic syndrome, acute glomerulonephritis, chronic renal failure, and corticosteroid and estrogen therapy. Hydrochlorothiazide is also indicated alone or in combination for the management of hypertension.
- Associated Conditions
- Calcium Nephrolithiasis, Cirrhosis of the Liver, Congestive Heart Failure (CHF), Diabetes Insipidus, Edema, Hypertension, Hypertension, Essential Hypertension, Hypokalemia caused by diuretics, Nephrotic Syndrome, Pre-Eclampsia, Premenstrual tension with edema, Renal tubular acidosis, Sodium retention, Stroke
HYZAAR vs. Ramipril for Diabetes (0954A-245)(COMPLETED)
- Conditions
- Type 2 Diabetes MellitusHypertension
- First Posted Date
- 2007-05-31
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 312
- Registration Number
- NCT00480805
Nijmegen Antihypertensive Management Improvement Study
- Conditions
- Primary Hypertension
- First Posted Date
- 2007-04-06
- Last Posted Date
- 2012-02-14
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 120
- Registration Number
- NCT00457483
- Locations
- 🇳🇱
Nijmegen monitoring project coordinated from Nijmegen, Nijmegen, Netherlands
A Study of Losartan Compared to Losartan/HCTZ in Pediatric Patients With Hypertension (0954A-327)
- Conditions
- Hypertension
- Interventions
- Drug: Placebo for Losartan/HCTZ
- First Posted Date
- 2007-03-15
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 40
- Registration Number
- NCT00447603
Efficacy and Safety of Valsartan in Combination With Amlodipine Compared to Losartan Plus Hydrochlorothiazide in Patients With Hypertension and Left Ventricular Hypertrophy
- Conditions
- Hypertension; Hypertrophy, Left Ventricular
- Interventions
- First Posted Date
- 2007-03-13
- Last Posted Date
- 2011-05-11
- Lead Sponsor
- Novartis
- Target Recruit Count
- 90
- Registration Number
- NCT00446563
- Locations
- 🇩🇪
25 centers in Germany, Ludwigshafen, Germany
Safety/Efficacy of Valsartan/Hydrochlorothiazide Combination Compared to Hydrochlorothiazide in Obese Hypertensive Adults
- First Posted Date
- 2007-02-26
- Last Posted Date
- 2017-05-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 412
- Registration Number
- NCT00439738
- Locations
- 🇺🇸
Terence T. Hart, MD, Muscle Shoals, Alabama, United States
🇺🇸Oklahoma Cardiovascular & Hypertension, Oklahoma City, Oklahoma, United States
🇺🇸Northeast Tarrant Internal Medicine Assoc, Euless, Texas, United States
Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2007-02-14
- Last Posted Date
- 2010-12-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2207
- Registration Number
- NCT00434967
- Locations
- 🇸🇰
Research Site, Sahy, Slovakia
Efficacy of Valsartan/Hydrochlorothiazide Versus Amlodipine and Hydrochlorothiazide in Patients Hypertension
- Conditions
- Hypertension
- First Posted Date
- 2007-01-24
- Last Posted Date
- 2011-06-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 480
- Registration Number
- NCT00425997
- Locations
- 🇺🇸
Sites in USA, East Hanover, New Jersey, United States
Effects of Intensive Long-Term Vasodilation in Hypertensive Patients With Microvascular Angina Pectoris
- Conditions
- Microvascular AnginaHypertension
- Interventions
- First Posted Date
- 2007-01-22
- Last Posted Date
- 2009-05-06
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 10
- Registration Number
- NCT00424801
- Locations
- 🇩🇰
Aarhus Hospital, Aarhus, Denmark
An Assessment of Long Term Safety of the Combination of Aliskiren / Amlodipine in Patients With High Blood Pressure
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2011-03-10
- Lead Sponsor
- Novartis
- Target Recruit Count
- 556
- Registration Number
- NCT00402103
- Locations
- 🇩🇪
Investigative Center, Investigative Center, Germany
🇧🇪Investigator Site, Investigative Site, Belgium
🇨🇭Investigative Site, Investigative Site, Switzerland
Efficacy and Safety of Valsartan, Hydrochlorothiazide and Amlodipine Combination Therapy in Hypertension
- Conditions
- Hypertension
- First Posted Date
- 2006-11-17
- Last Posted Date
- 2008-06-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 460
- Registration Number
- NCT00400777
- Locations
- 🇧🇷
Novartis, Rio de Janeiro, Brazil
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.